Roles of oxidative stress and Akt signaling in doxorubicin cardiotoxicity

被引:43
作者
Ichihara, Sahoko
Yamada, Yoshiji
Kawai, Yoshichika
Osawa, Toshihiko
Furuhashi, Koichi
Duan, Zhiwen
Ichihara, Gaku
机构
[1] Mie Univ, Life Sci Res Ctr, Dept Human Funct Genom, Tsu, Mie 5148507, Japan
[2] Nagoya Univ, Grad Sch Med, Nagoya, Aichi, Japan
[3] Nagoya Univ, Grad Sch Bioagr Sci, Lab Food & Biodynam, Nagoya, Aichi, Japan
[4] Univ Tokushima, Dept Food Sci, Grad Sch Nutr & Biosci, Tokushima 770, Japan
[5] Shenyang Med Coll, Dept Toxicol, Shenyang, Peoples R China
关键词
doxorubicin; heart failure; oxidative stress; apoptosis; angiogenesis; fenofibrate; superoxide dismutase;
D O I
10.1016/j.bbrc.2007.05.027
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cardiotoxicity is a treatment-limiting side effect of the anticancer drug doxorubicin (DOX). We have now investigated the roles of oxidative stress and signaling by the protein kinase Akt in DOX-induced cardiotoxicity as well as the effects on such toxicity both of fenofibrate, an agonist of peroxisome proliferator-activated receptor-alpha, and of polyethylene glycol-conjugated superoxide dismutase (PEG-SOD), an antioxidant. Mice injected intraperitoneally with DOX were treated for 4 days with fenofibrate or PEG-SOD. Fenofibrate and PEG-SOD each prevented the induction of cardiac dysfunction by DOX. Both drugs also inhibited the activation of the transcription factor NF-kappa B and increase in lipid peroxidation in the left ventricle induced by DOX, whereas only PEG-SOD inhibited the DOX-induced activation of Akt and Akt-regulated gene expression. These results suggest that fenofibrate and PEG-SOD prevented cardiac dysfunction induced by DOX through normalization of oxidative stress and redox-regulated NF-KB signaling. (C) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:27 / 33
页数:7
相关论文
共 31 条
[1]  
Arola OJ, 2000, CANCER RES, V60, P1789
[2]   ADRIAMYCIN - NEW ANTICANCER DRUG WITH SIGNIFICANT CLINICAL ACTIVITY [J].
BLUM, RH ;
CARTER, SK .
ANNALS OF INTERNAL MEDICINE, 1974, 80 (02) :249-259
[3]   Doxorubicin selectively inhibits brain versus atrial natriuretic peptide gene expression in cultured neonatal rat myocytes [J].
Chen, SC ;
Garami, M ;
Gardner, DG .
HYPERTENSION, 1999, 34 (06) :1223-1231
[4]  
DEL PL, 1997, SCIENCE, V278, P687
[5]   Prevention of doxorubicin-induced acute cardiotoxicity by an experimental antioxidant compound [J].
Deres, P ;
Halmosi, R ;
Toth, A ;
Kovacs, K ;
Palfi, A ;
Habon, T ;
Czopf, L ;
Kalai, T ;
Hideg, K ;
Sumegi, B ;
Toth, K .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2005, 45 (01) :36-43
[6]   PPARα activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats [J].
Diep, QN ;
Benkirane, K ;
Amiri, F ;
Cohn, JS ;
Endemann, D ;
Schiffrin, EL .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2004, 36 (02) :295-304
[7]   PREVENTION OF DOXORUBICIN CARDIAC TOXICITY IN THE MOUSE BY N-ACETYLCYSTEINE [J].
DOROSHOW, JH ;
LOCKER, GY ;
IFRIM, I ;
MYERS, CE .
JOURNAL OF CLINICAL INVESTIGATION, 1981, 68 (04) :1053-1064
[8]   A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics Adriamycin and daunorubicin [J].
Gewirtz, DA .
BIOCHEMICAL PHARMACOLOGY, 1999, 57 (07) :727-741
[10]   Cardiac myocyte-specific HIF-1α deletion alters vascularization, energy availability, calcium flux, and contractility in the normoxic heart [J].
Huang, Y ;
Hickey, RP ;
Yeh, JL ;
Liu, DG ;
Dadak, A ;
Young, LH ;
Johnson, RS ;
Giordano, FJ .
FASEB JOURNAL, 2004, 18 (07) :1138-+